Diabetes worsening of hepatitis C cirrhosis: Are alterations in monocytic tissue factor (CD 142) is the cause?

AbstractBackground & Aim. The mechanisms by which type 2 diabetes mellitus (T2DM) worsen liver function are not yet established. Tissue factor (TF) is a protein that participates in hemostatic, immune and inflammatory processes. To test the hypothesis that T2DM contributes to clinical outcome th...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of hepatology Vol. 13; no. 1; pp. 27 - 37
Main Authors:	Makarem, Mona A. Abu El, Eslam, Mohammed, Sayed, Douaa, Shawkat, Mohamed, Idriss, Naglaa K, Soliman, Elwy M, Sherif, Tahra, Abdelshaheed, Ragaa, Abdelhailm, Hesham, Sahrawi, Mohamed A, Elheney, Sahar
Format:	Journal Article
Language:	English
Published:	Mexico Elsevier 2014
Subjects:	Adult Antidiabetic therapies B7-2 Antigen - metabolism Case-Control Studies Child-Pugh score Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Female Flow Cytometry Flowcytometry Gastroenterology and Hepatology Hepatitis C, Chronic - complications Hepatitis C, Chronic - metabolism HLA-DR Antigens - metabolism Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Lipopolysaccharide Receptors - metabolism Liver Cirrhosis - complications Liver Cirrhosis - metabolism Male Middle Aged Monocytes - metabolism Prospective Studies Thromboplastin - metabolism Flowcytometry Child-Pugh score Antidiabetic therapies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	AbstractBackground & Aim. The mechanisms by which type 2 diabetes mellitus (T2DM) worsen liver function are not yet established. Tissue factor (TF) is a protein that participates in hemostatic, immune and inflammatory processes. To test the hypothesis that T2DM contributes to clinical outcome through changes of TF expression on monocytes and to investigate the association between antidiabetic therapies and monocytic TF expression in HCV-related cirrhotic patients with T2DM. Material and methods. In HCV-related cirrhotic patients (139 diabetics and 130 non diabetics) compared with 100 matched diabetic patients and 100 Controls; the flowcytometric analysis of CD14, TF (CD142), costimulatory molecules; CD86 and HLA-DR on monocytes were determined. Results. Cirrhotic patients with T2DM have increase in the expression of monocytic TF and CD86 in comparison with cirrhotic non-diabetic, diabetic and healthy control; which increase significantly with increase of the stage of the Child-Pugh score. The expression of HLA-DR is significantly lower in cirrhotic patients than controls. Albeit, there were no significant differences in the HbA1c levels between the three groups, the use of exogenous insulin were associated with significantly higher monocytic TF expression than those in sulphonylurea and insulin sensitizer group (P < 0.03 for both). Conclusions. The monocytic TF as a significant link connecting inflammatory and immunological phenomena can partially explain a lot of events in HCV-related cirrhotic patients with T2DM. The use of exogenous insulin was associated with significantly higher TF expression than sulphonylurea and insulin sensitizer. Future target therapy against TF may be beneficial for T2DM cirrhotic patients.
ISSN:	1665-2681
DOI:	10.1016/S1665-2681(19)30901-9